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Abstract Metformin is a widely-used drug that results in
clear benefits in relation to glucose metabolism and
diabetes-related complications. The mechanisms underlying
these benefits are complex and still not fully understood.
Physiologically, metformin has been shown to reduce hepatic
glucose production, yet not all of its effects can be explained
by this mechanism and there is increasing evidence of a key
role for the gut. At the molecular level the findings vary de-
pending on the doses of metformin used and duration of treat-
ment, with clear differences between acute and chronic admin-
istration. Metformin has been shown to act via both AMP-
activated protein kinase (AMPK)-dependent and AMPK-
independent mechanisms; by inhibition of mitochondrial res-
piration but also perhaps by inhibition of mitochondrial glyc-
erophosphate dehydrogenase, and a mechanism involving the
lysosome. In the last 10 years, we have moved from a simple
picture, that metformin improves glycaemia by acting on the
liver via AMPK activation, to a much more complex picture
reflecting its multiple modes of action. More work is required
to truly understand how this drug works in its target popula-
tion: individuals with type 2 diabetes.
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Abbreviations
ACC Acetyl-CoA carboxylase
AICAR 5-Aminoimidazole-4-carboxamide ribonucleoside
AMPK AMP-activated protein kinase
EGP Endogenous glucose production
FDG Fluorodeoxyglucose
G6Pase Glucose-6-phosphatase
GI Gastrointestinal
GLP-1 Glucagon-like peptide-1
mGPD Mitochondrial glycerophosphate dehydrogenase
NLR Neutrophil to lymphocyte ratio
OCT1 Organic cation transporter 1
PET Positron emission tomography
PKA Protein kinase A
SERT Serotonin transporter
ZMP 5-Amino-4-imidazolecarboxamide riboside 5′-
monophosphate
Introduction
Metformin and the related drug phenformin (the latter with-
drawn from diabetes treatment in most countries because of
side effects of lactic acidosis) are derived from galegine, a
natural product from the plantGalega officinalis, used in herb-
al medicine in medieval Europe. Galegine was tested as a
glucose-lowering agent in humans in the 1920s but was found
to be too toxic [1, 2]. At about the same time, two synthetic
derivatives of galegine, metformin and phenformin, were first
synthesised and tested, although they were not introduced to
clinical use until the 1950s [3]. Chemically, galegine is an
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isoprenyl derivative of guanidine, while metformin and
phenformin are biguanides containing two coupled molecules
of guanidine with additional substitutions (Fig. 1). Unlike
most modern drugs, metformin is therefore derived from a
natural product used in herbal medicine and was not designed
to target a particular pathway or disease mechanism. It was
established as a safe and effective therapy before detailed
mechanistic studies became possible and, despite its clinical
use for 60 years, its molecular mechanisms of action remain
much debated. In this brief review, we summarise the current
evidence highlighting how metformin’s benefits are likely to
be caused by a variety of molecular mechanisms.
Following oral dosing of immediate-release metformin in
humans, approximately 70% of the dose is absorbed from the
small intestine with the remainder passing into the colon be-
fore being excreted in faeces [4]. Metformin is excreted in
urine unchanged, with no metabolites reported. Plasma con-
centrations of metformin in humans are typically in the low
micromolar range (e.g. 8–24 μmol/l) but are 30–300 times
higher in jejunal samples [5]. A recent [11C]metformin posi-
tron emission tomography (PET) study demonstrated that oral
metformin becomes highly concentrated in the intestines, liv-
er, kidneys and bladder (reflecting its route of elimination),
with only slow accumulation in muscle [6]. In this study, the
hepatic tissue:systemic blood activity was ~5 following oral
dosing of the metformin tracer, demonstrating that much
greater metformin concentrations are achieved in the liver than
in the plasma; extrapolating from systemic concentrations
would estimate hepatic concentrations post-oral dose at ~50–
100 μmol/l. In rats dosed with i.v. metformin, metformin ac-
cumulation was observed in the pancreas and adipose tissue at
a concentration of approximately half that seen in the liver [7];
how this translates to humans is unclear. The human pharma-
cokinetic data point to the liver, kidney and intestines as the
key target organs of metformin and in this review we will
primarily focus on the liver and intestines, particularly when
referring to the beneficial impact of metformin on metabolism
and inflammation. Other mechanisms relating to potential car-
diovascular benefits, cancer prevention and ageing are cov-
ered elsewhere in this issue of Diabetologia [8–10].
Metformin and the liver
Metformin is traditionally thought to act on the liver to im-
prove blood glucose levels and several lines of evidence sup-
port this. First, in mice lacking the organic cation transporter 1
(OCT1), which take up little or no metformin into the liver
[11], metformin was ineffective at improving blood glucose
after high-fat feeding [12]. Second, tracer studies in humans
show that metformin lowers hepatic glucose production, with
minimal impact on peripheral insulin-mediated glucose up-
take. However, when only placebo-controlled studies were
analysed, the impact of metformin on endogenous glucose
production (EGP) was not significant unless concomitant
drug-induced reductions in plasma insulin were used to ‘ad-
just’ EGP [13]. Third, as will be summarised here, multiple
studies in mouse hepatocytes and transgenic mice provide
evidence for a role of metformin in reducing hepatic gluco-
neogenesis and/or insulin sensitivity.
Metformin and the mitochondrial control of hepatic glu-
coneogenesis Given that gluconeogenesis is an energy-
intensive process (consuming six ATP equivalents per mole-
cule of glucose synthesised), hepatocytes need to balance the
demand for ATP with supply, with the latter primarily provid-
ed by mitochondria. Metformin accumulates within mito-
chondria to concentrations up to 1000-fold higher than in the
extracellular medium, because metformin carries a positive
charge and the membrane potentials across the plasma mem-
brane and mitochondrial inner membrane (positive outside)
drive metformin into the cell and subsequently into the mito-
chondria (Fig. 2) [14, 15]. The most intensively studied mito-
chondrial action of metformin is the inhibition of Complex I
of the respiratory chain [14, 16], which suppresses ATP pro-
duction. A persistent criticism of this mechanism has been the
high extracellular concentrations (mmol/l) required to observe
rapid effects, although lower concentrations of metformin
(50–100 μmol/l) do inhibit Complex I in rat hepatoma
(H4IIE) cells after several hours; this delay was ascribed to
the slow uptake ofmetformin bymitochondria [14], which has
recently been observed experimentally [15]. In addition, some
studies do not detect any changes in cellular ADP:ATP ratios
after metformin treatment, although they can be observedwith
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Fig. 1 Chemical structures of galegine, metformin and phenformin.
Metformin and phenformin are synthetic derivatives of galegine.
Chemically, (a) galegine (also known as isoprenylguanidine), is an
isoprenyl der iva t ive of guanid ine , whi le (b ) metformin
(dimethylbiguanide) and (c) phenformin (phenethylbiguanide) are
biguanides containing two coupledmolecules of guanidine with addition-
al substitutions
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Fig. 2 The multiple mechanism via which metformin affects liver me-
tabolism. Note that the possible effect of metformin on mitochondrial
glycerophosphate dehydrogenase [7] has not been included. (1) Uptake
of metformin into hepatocytes is catalysed by the organic cation trans-
porter-1 (OCT1) [11]. Being positively charged, the drug accumulates in
cells and, further, in the mitochondria because of the membrane potentials
across the plasma membrane and themitochondrial inner membrane [14].
(2)Metformin inhibits Complex I, preventingmitochondrial ATP produc-
tion and, thus, increasing cytoplasmic ADP:ATP and AMP:ATP ratios
(the latter by displacement of the adenylate kinase reaction); these chang-
es activate AMPK [17]. (3) Alternatively, AMPK may be activated by a
lysosomal mechanism, not shown in detail here but requiring Axin and
late endosomal/lysosomal adaptor, MAPK and mTOR activator 1
(LAMTOR1) [27]. (4) Increases in AMP:ATP ratio also inhibit fruc-
tose-1,6-bisphosphatase (FBPase), resulting in the acute inhibition of glu-
coneogenesis [30], while also inhibiting adenylate cyclase and lowering
cAMP production [32]. (5) Activated AMPK phosphorylates the ACC1
and ACC2 isoforms of ACC, inhibiting fat synthesis and promoting fat
oxidation instead, thus reducing hepatic lipid stores and enhancing hepat-
ic insulin sensitivity [34]. (6) AMPK also phosphorylates and activates
the cAMP-specific 3′,5′-cyclic phosphodiesterase 4B (PDE4B), thus
lowering cAMP by another mechanism [33]. (7) Glucagon-induced in-
creases in cAMP activate cAMP-dependent protein kinase A (PKA),
causing a switch from glycolysis to gluconeogenesis via phosphorylation
and inactivation of PFKFB1, causing a decrease in fructose-2,6-
bisphosphate (F2,6BP), an allosteric activator of phosphofructokinase
(PFK) and inhibitor of fructose-1,6-bisphosphatase (FBPase). (8) PKA
also phosphorylates and inactivates the liver isoform of the glycolytic
enzyme pyruvate kinase (Pyr K) and (9) phosphorylates the transcription
factor cAMP response element binding protein (CREB), thus inducing
transcription of the genes encoding the gluconeogenic enzymes PEPCK
and G6Pase. (10) Phosphorylation of CREB-regulated transcriptional co-
activator-2 (CRTC2) by AMPK, or by AMPK-related kinases such as
salt-inducible kinase 2 (SIK2), causes CRTC2 to be retained in the cyto-
plasm, antagonising the effects of PKA on the transcription of PEPCK
and G6Pase [61, 62]. PKA inhibits SIK2 by direct phosphorylation at
multiple sites [62]. Ac-CoA, acetyl-CoA; BPG, 1,3-bisphosphoglycerate;
DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphate;
F6P, fructose 6-phosphate; G3P, glyceraldehyde 3-phosphate; G6P, glu-
cose 6-phosphate; Ma-CoA, malonyl-CoA; OAA, oxaloacetate; PEP,
phosphoenolpyruvate; 3PG, 3-phosphoglycerate
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phenformin [17]. In cells carrying out gluconeogenesis, con-
comitant suppression of this pathway [18] might explain mod-
est effects on ADP:ATP ratios. Other consequences of respi-
ratory chain inhibition besides ATP production, such as
changes in the NAD+:NADH ratio, may also contribute to
the effects of metformin on gluconeogenesis [16].
Recently, an alternative mitochondrial target of metformin
has been proposed [7]. EGP (primarily by the liver) was
inhibited after just 1 h of i.v. administration of metformin to
rats and this was associated with an increase in the
lactate:pyruvate ratio, suggesting a problem with re-
oxidation of cytoplasmic NADH. The glycerophosphate shut-
tle is one of two systems that carry reducing equivalents from
the cytoplasm into the mitochondrion for re-oxidation. In cell-
free assays, metformin was found to inhibit mitochondrial
glycerophosphate dehydrogenase (mGPD), a key component
of this shuttle. Supporting this mechanism, i.p. administration
of antisense oligonucleotides against mGPD, or a global
mouse knockout, were found to lower EGP and abolish the
effects of metformin on plasma glucose and EGP. However, as
discussed by others, inhibition of the glycerophosphate shuttle
alone may not be sufficient for a sustained impact on gluco-
neogenesis because the malate/aspartate shuttle will compen-
sate unless the mitochondrial membrane potential (which is
maintained by the respiratory chain) also becomes suppressed
[19]. Thus, the relative contributions of inhibition of mGPD
and Complex I in metformin’s glucose-lowering effects need
to be established, as does the possible role of its less well
understood effects on membrane properties [20] and on inter-
actions and oxidation of amino acid-bound copper ions
[21–23].
Molecular mechanisms for metformin-associated AMPK
activation Inhibition of mitochondrial function can also ex-
plain metformin’s ability to activate the cellular energy sensor
AMP-activated protein kinase (AMPK). Once activated by
increases in AMP:ATP and ADP:ATP ratios (indicative of
cellular energy balance being compromised), AMPK acts to
restore energy homeostasis by switching on catabolic path-
ways generating ATP, while switching off cellular processes
consuming ATP (Fig. 2) [24, 25]. Since it causes a switch from
synthesis of cellular nutrient stores to their breakdown, the
idea that AMPK might be involved in metformin action was
attractive and, in 2001, metformin was reported to activate
AMPK in rat hepatocytes and rat liver in vivo [26].
Although high concentrations (500 μmol/l) of metformin
were required to observe AMPK activation after brief (1 h)
treatment of cells, significant effects were observed after in-
cubation for much longer periods with just 20 μmol/l metfor-
min, more compatible with concentrations of the drug found
in the portal vein. Supporting the idea that biguanides acted by
increasing cellular AMP:ATP/ADP:ATP ratios, AMPK was
not activated by either metformin or phenformin in cells
expressing an AMPK mutant that is insensitive to changes in
AMP or ADP [17]. However, AMPK can also be activated by
glucose starvation, and by low concentrations of metformin,
by a different mechanism involving the formation of a com-
plex with the proteins Axin and late endosomal/lysosomal
adaptor, MAPK and mTOR activator 1 (LAMTOR1; Fig. 2),
the latter being a lysosomal protein [27]. Thus, metformin
might also activate AMPK by a mechanism involving the
lysosome, rather than the mitochondrion.
AMPK-dependent and -independent effects of metformin
on hepatic gluconeogenesis The first pharmacological acti-
vator of AMPK to be developed was 5-aminoimidazole-4-
carboxamide ribonucleoside (AICAR), a nucleoside that is
taken up into cells and phosphorylated to the nucleotide 5-
amino-4-imidazolecarboxamide riboside 5′-monophosphate
(ZMP), which mimics all effects of AMP on the AMPK
system [28]. The finding that AICAR downregulated expres-
sion of the gluconeogenic enzymes PEPCK and glucose-6-
phosphatase (G6Pase; Fig. 2) [29] initially supported the idea
that AMPK activation might be responsible for the ability of
metformin to inhibit hepatic glucose production. However, an
important caveat is that ZMP also modulates other AMP-
sensitive enzymes such as fructose-1,6-bisphosphatase, a
key enzyme of gluconeogenesis that is allosterically inhibited
by both AMP and ZMP [30]. Tellingly, acute treatment with
metformin or AICAR inhibited glucose production equally
well in hepatocytes from control mice or mice lacking both
AMPK catalytic subunits in the liver, while metformin acutely
improved glucose tolerance in both mouse strains [31].
Metformin did increase cellular AMP:ATP ratios in hepato-
cytes [31], consistent with inhibition of the respiratory chain.
It seems likely that the acute inhibition of glucose production
bymetformin or AICARwas due to inhibition of fructose-1,6-
bisphosphatase by AMP or ZMP, respectively. However, ex-
pression of mRNAs encoding G6Pase and PEPCK was also
reduced by AICAR and metformin in both control and
AMPK-null hepatocytes. A potential explanation for this
came with a report that adenylate cyclase, which generates
cAMP in response to the starvation hormone glucagon in
mouse hepatocytes is (like fructose-1,6-bisphosphatase)
inhibited by AMP. Thus, AMP might have an additional
AMPK-independent effect, lowering cAMP and reducing ex-
pression of gluconeogenic enzymes [32]. More recently, an-
other group has proposed an AMPK-dependent mechanism
by which metformin reduces cAMP [33]: treatment of mouse
hepatocytes with a more specific AMPK activator reduced
glucagon-induced cAMP levels and this was traced to the
direct AMPK-mediated phosphorylation of the cAMP-
specific 3′,5′-cyclic phosphodiesterase 4B (PDE4B), trigger-
ing cAMP breakdown (Fig. 2).
While controversies therefore remain, it seems certain that
some of the acute effects of metformin on hepatic glucose
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production are AMPK-independent, with inhibition of fruc-
tose-1,6-bisphosphatase by AMP being one likely explana-
tion. However, a major long-term, clinically relevant effect
of metformin is to enhance hepatic insulin sensitivity and
mouse studies suggest that this is mediated by AMPK.
AMPK acutely inhibits fat synthesis and activates fat oxida-
tion in the liver by direct phosphorylation of the two isoforms
of acetyl-CoA carboxylase (ACC1/ACC2) at equivalent ser-
ine residues. Knock-in mice were generated in which both
serine residues were replaced by non-phosphorylatable ala-
nine residues (ACC1-S79A and ACC2-S212A) [34].
Consistent with the prediction that this would enhance fat
synthesis and reduce fat oxidation, these mice (although not
obese) had elevated diacylglycerol and triacylglycerol levels
in liver and muscle. Consistent with this steatosis, the mice
were hyperglycaemic, hyperinsulinaemic, glucose intolerant
and insulin resistant, even on a normal chow diet. When con-
trols were placed on a high-fat diet for 6 weeks they became
just as hyperglycaemic and glucose intolerant as the knock-in
mice. However, while the metabolic measures of the high-fat
fed control mice substantially improved after 6 weeks of treat-
ment with metformin, those of the knock-in mice were unaf-
fected [34]. These intriguing results suggest that metformin
enhances insulin sensitivity, at least in mice, by phosphoryla-
tion of ACC1 and ACC2 (as shown in Fig. 2). Since ACC
phosphorylation is abolished by AMPK knockout [31], the
long-term insulin-sensitising effects of metformin appear to
be mediated entirely by AMPK.
Metformin and the intestines
It has been known for some time that the intestines may be a
target organ for metformin [5, 35], with metformin increasing
anaerobic glucose metabolism in enterocytes, resulting in re-
duced net glucose uptake and increased lactate delivery to the
liver. Several recent studies have led to a renewed interest in
the gut as a major site of action of metformin and three lines of
evidence highlight that the liver may not be as important for
metformin action in individuals with type 2 diabetes as com-
monly assumed. First, the glucose-lowering effect of metfor-
min can only partially be explained by a reduction in EGP,
suggesting other glucose-lowering mechanisms for metformin
[13]. Second, genetic studies in humans have established that
loss-of-function variants in SLC22A1 (the gene encoding
OCT1), which reduce hepatic uptake of metformin [36], do
not impact upon the efficacy of metformin to lower HbA1c in
individuals with type 2 diabetes [37, 38]. Third, a delayed-
release metformin that is largely retained in the gut, with min-
imal systemic absorption, is as effective at lowering blood
glucose as the standard immediate-release formulation in in-
dividuals with type 2 diabetes [39].
There are a number of putative mechanisms for how met-
formin could impact on glucose metabolism via actions on the
intestines (reviewed in [40]). As already mentioned, metfor-
min increases glucose utilisation by the gut; an effect that is
apparent in PET imaging, where metformin-treated patients
show considerable intestinal fluorodeoxyglucose (FDG) up-
take, especially in the colon. A recent study in mice
established that colonic FDG uptake was not increased after
48 h of metformin treatment, but was increased after 30 days
of treatment, an effect that persisted despite 48 h of metformin
washout [41]. The increase in FDG uptake was paralleled by
an increase in AMPK phosphorylation and, like the FDG up-
take, this effect was only seen in colonic enterocytes where
luminal glucose was almost absent, suggesting that metformin
increases colonic uptake and metabolism of systemic glucose.
Metformin may also impact on glucose metabolism by in-
creasing glucagon-like peptide-1 (GLP-1) secretion, an effect
that is described for both immediate-release [42] and delayed-
release [43] metformin. A further intriguing gut-mediated
mechanism for metformin action was identified in rats and
involves a pathway linking duodenal metformin exposure to
suppression of hepatic glucose production, via the nucleus
tractus solitarius and vagal efferents, through AMPK and
GLP-1 receptor activation (gut–brain–liver crosstalk, Fig. 3)
[44]. A final potential gut-mediated mechanism of action of
metformin involves alteration of the intestinal microbiome
(Fig. 3), which is outlined below in relation to inflammation;
how this contributes to the glucose-lowering and gastrointes-
tinal (GI) side effects of metformin is unknown.
Metformin intolerance Metformin treatment is frequently
associated with GI side effects (20–30% of patients) [45] with
severe side effects resulting in metformin discontinuation in
~5% of patients. The mechanism by which metformin causes
GI side effects remains uncertain. However, there are a num-
ber of putative mechanisms; the side effects may simply relate
to the high concentration of metformin in intestinal
enterocytes, potentially explaining why slow-release formula-
tions of metformin, which disperse slowly and reduce local
luminal metformin concentrations, reduce GI intolerance. An
alternative mechanism may involve serotonin, either as a re-
sult of stimulation of serotonin release from enterochromaffin
cells [46], or by reducing serotonin transport via the serotonin
transporter (SERT), resulting in increased luminal serotonin.
Genetic studies have identified a key role for OCT1 and SERT
in mediating metformin intolerance [47, 48]. A third potential
mechanism of intolerance may be due to the impact of met-
formin on the intestinal microbiome (see later). Further studies
are required to establish the mechanisms for metformin intol-
erance as this may enable approaches to reduce or avoid the
unpleasant side effects of this drug. For example, the studies
we report on the role of OCT1 inmetformin intolerance would
support an approach whereby OCT1-interacting drugs (such
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as proton pump inhibitors) are avoided in individuals
experiencing GI side effects with metformin use [47].
Inflammation, ageing and the impact
of the microbiome
In the nematode worm, Caenorhabditis elegans, metformin
lengthens lifespan through effects on intestinal microbial
growth [49]. Consistent with this interesting concept of
metformin’s ability to affect host metabolism indirectly,
metformin expanded the gut population of Akkermansia
spp. in animal studies, which was linked to reduced adi-
pose tissue inflammation and suppressed postprandial
hyperglycaemia [50]. More recent studies in humans found
that metformin-dependent increases in Escherichia
spp. and decreases in Intestinibacter spp. were the most
consistently observed effects on the microbiome across datasets
from different countries [51]. This recent work emphasises that
microbiome changes in type 2 diabetes are predominantly asso-
ciated with metformin, rather than type 2 diabetes itself, although
their role as cause or consequence of therapeutic benefit requires
further investigation.Metformin has, for example, been shown to
have direct effects on inflammation, including effects on NF-κB
signalling and differentiation of monocytes into macrophages
[52, 53], as well as suppressing proinflammatory cytokines from
these macrophages. Consistent with this, metformin suppresses
the neutrophil to lymphocyte ratio (NLR) in type 2 diabetes
(Fig. 3). NLR is a marker of inflammation that has recently been
found to be a predictor of all-cause mortality and cardiac events.
In addition, metformin suppresses several inflammatory cyto-
kines in human plasma in individuals without diabetes [53].
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Fig. 3 Actions of metformin on metabolism and inflammation.
Responses to metformin in the blood, liver and intestines are shown
schematically. In the blood, in observational studies, NLR is suppressed
in humans with type 2 diabetes, whilst in randomised placebo-controlled
trials, cytokines, including C-Cmotif chemokine 11 (CCL11, also known
as eotaxin-1), are also shown to be suppressed with metformin treatment.
Other results indicate effects of this drug onmonocytes and macrophages,
affecting monocyte differentia t ion into macrophages and
proinflammatory (proinflam) cytokine secretion. In the intestines, gut
metabolism, incretin (GLP-1) secretion and the microbiome are modified
upon metformin use. Further, there is evidence for gut-mediated mecha-
nism for metformin action via gut–brain–liver crosstalk, which indirectly
regulates hepatic glucose output. In the liver, metformin decreases lipo-
genesis and gluconeogenesis, as a result of its impact on molecular sig-
nalling and on mitochondrial function. HGP; hepatic glucose production;
mTOR, mammalian target of rapamycin
1582 Diabetologia (2017) 60:1577–1585
Interestingly, one of the cytokines suppressed bymetformin is C-
C motif chemokine 11 (CCL11), which has previously been
found to contribute to age-related cellular and tissue dysfunction.
It is possible that recent observations, consistent with the ability
of metformin to prolong mammalian lifespan [54, 55], may, at
least in part, be due to suppression of this cytokine. Metformin
may also control longevity through regulation of mammalian
target of rapamycin (mTOR) signalling, which is observed in
mammals and C. elegans [56, 57], with AMPK-dependent and
-independent mechanisms identified [57].
Insights from genetic studies of metformin action
in humans
Recently, genome-wide association studies have been under-
taken to assess genetic contributions to glycaemic responses to
metformin. These offer a complementary route to mouse and
cellular studies and have the advantage that they may reveal
the mechanisms of action of metformin in humans with type 2
diabetes without making prior assumptions about these mech-
anisms. These studies are covered in more detail in the phar-
macogenetics of metformin review in this issue of
Diabetologia [58], but we briefly mention here two investiga-
tions that identified novel targets for metformin action. The
first study reported on a locus on chromosome 11 involving
seven genes, one of which was the ataxia telangiectasia mu-
tated gene (ATM) [59]; recessive mutations in this gene cause
ataxia telangiectasia, a condition associated with fatty liver,
insulin resistance and diabetes. The second identified an
SNP in the SLC2A2 gene, which was associated with altered
GLUT2 expression in the liver and other tissues [60]. These
genes were not previously thought to be involved in the mech-
anisms ofmetformin action, and clinical andmechanistic stud-
ies are ongoing to address the role of these genes in both the
liver and the gut.
Conclusions
Metformin is a complex drug with multiple sites of action and
multiple molecular mechanisms. Physiologically, metformin
acts directly or indirectly on the liver to lower glucose produc-
tion, and acts on the gut to increase glucose utilisation, in-
crease GLP-1 and alter the microbiome. At the molecular
level, metformin inhibits the mitochondrial respiratory chain
in the liver, leading to activation of AMPK, enhancing insulin
sensitivity (via effects on fat metabolism) and lowering cAMP,
thus reducing the expression of gluconeogenic enzymes.
Metformin also has AMPK-independent effects on the liver
that may include inhibition of fructose-1,6-bisphosphatase by
AMP. As cell and tissue responses are not only a product of
dose, but also of treatment duration and model used, we
suggest that the physiological relevance of the effects of met-
formin identified in cells is best validated through studies
carried out in vivo, ideally in humans given metformin by
the oral route. Further, pharmacogenetic studies in humans,
and careful physiological validation of cell-based metformin
studies, focusing on intestinal, hepatic and renal effects are
warranted to enable a more robust appreciation of the key
mechanisms that are active in long-term treatment with met-
formin in humans.
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